Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab
Latest Information Update: 14 Feb 2025
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms STARDUST; STARDUST LTE
- Sponsors Janssen-Cilag
- 30 Nov 2023 Results (n=323) from long-term extension period assessing clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease through week 104 published in the Alimentary Pharmacology and Therapeutics
- 11 Oct 2022 Results (n=323) assessing the long-term extension period for health-related quality of life measures and the effect of ustekinumab on work productivity and activity impairment at week 104, comparing treat-to-target and standard of care, presented at the 30th United European Gastroenterology Week.
- 11 Oct 2022 Results of incorporated-intestinal ultrasound sub-study (n=77) assessing incorporated-intestinal ultrasound endpoints and their relation-ship with ustekinumab exposure presented at the 30th United European Gastroenterology Week.